Maxcyte (MXCT) Total Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Liabilities data on file, last reported at $26.6 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 12.97% year-over-year to $26.6 million in Q1 2026; TTM through Mar 2026 was $26.6 million, a 12.97% decrease from a year earlier, with the FY2025 full-year figure at $31.0 million, down 6.63% from the prior year.
• Total Liabilities for Q1 2026 stood at $26.6 million, down from $31.0 million in the prior quarter.
• Over the last five years, Total Liabilities for MXCT reached as high as $36.1 million in Q4 2023 and fell as low as $26.6 million in Q1 2026.
• Historically, Total Liabilities has averaged $31.8 million across 5 years, with a median of $32.0 million in 2022.
• Across the five-year window, Total Liabilities surged 135.6% in 2022 and dropped 12.97% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $32.7 million in 2022, then grew by 10.47% to $36.1 million in 2023, then dropped by 8.0% to $33.2 million in 2024, then fell by 6.63% to $31.0 million in 2025, then declined by 14.28% to $26.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $26.6 million in Q1 2026, $31.0 million in Q4 2025, and $33.2 million in Q3 2025.